retatrutide drug retatrutide clinical trials ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide Phase 3: 60% Achieved
Description
Who can benefit from GLP-1 receptor agonists
Ideal candidates include adults with: BMI 30 (obesity) BMI 27 with weight-related conditions (type 2 diabetes, hypertension, high cholesterol, sleep apnea, PCOS) Inability to lose weight through diet and exercise alone Contraindications include: Personal or family history of medullary thyroid carcinoma Multiple endocrine neoplasia syndrome type 2 (MEN 2) History of pancreatitis (caution advised) Your online doctor will evaluate all risks and benefits before prescribing
Drop back by at least one escalation step and work up again
Key takeaway for weeks 24 Weeks 24 are where consistency starts to compound
Analysis by Location of Headquarters 6.2.3
10.1038/s41598-021-94595-6 68 MurakamiT.FujimotoH.InagakiN
